Chemexpress(SH:688131) Xin Lang Cai Jing·2025-09-12 08:55Core Viewpoint - Haoyuan Pharmaceutical experienced a 5.1% increase in stock price, reaching 74.00 CNY per share, with a total market capitalization of 15.695 billion CNY as of September 12 [1] Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. was established on September 30, 2006, and went public on June 8, 2021. The company specializes in the discovery of small molecule drugs, focusing on molecular building blocks and tool compounds, as well as the development and production of active pharmaceutical ingredients (APIs) and intermediates [1] - The main revenue sources for the company include molecular building blocks, tool compounds, and biochemical reagents, accounting for 68.97% of total revenue. Product sales contribute 63.42%, while APIs and intermediates, along with formulations, account for 30.46%. Technical services make up 5.55%, and other sources contribute 0.57% [1] Shareholder Information - Among the top circulating shareholders of Haoyuan Pharmaceutical, a fund under China Europe Fund holds a significant position. The China Europe Healthcare Mixed A Fund (003095) reduced its holdings by 2.7776 million shares in the second quarter, retaining 6.1185 million shares, which represents 2.97% of the circulating shares. The estimated floating profit from this transaction is approximately 21.9653 million CNY [2] - The China Europe Healthcare Mixed A Fund was established on September 29, 2016, with a current scale of 15.638 billion CNY. Year-to-date returns stand at 31.02%, ranking 2473 out of 8174 in its category, while the one-year return is 47.65%, ranking 3246 out of 7981. Since its inception, the fund has achieved a return of 126.12% [2] Fund Management - The fund manager of China Europe Healthcare Mixed A is Ge Lan, who has been in the position for 10 years and 230 days, overseeing assets totaling 39.908 billion CNY, with the best fund return during her tenure being 126.12% and the worst being -35.13% [3] - Co-manager Zhao Lei has been in the role for 71 days, managing assets of 30.801 billion CNY, with the best return being 17.59% and the worst being 17.42% during his tenure [3]